181 related articles for article (PubMed ID: 28835285)
1. Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs.
Maeda K; Kaneko M; Narukawa M; Arato T
Orphanet J Rare Dis; 2017 Aug; 12(1):143. PubMed ID: 28835285
[TBL] [Abstract][Full Text] [Related]
2. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis.
Michaeli T; Jürges H; Michaeli DT
BMJ; 2023 May; 381():e073242. PubMed ID: 37160306
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
Kesselheim AS; Myers JA; Avorn J
JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
[TBL] [Abstract][Full Text] [Related]
4. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
[TBL] [Abstract][Full Text] [Related]
5. The actual status of drug prices and adjustment factors for drug price calculation: an analysis of ultra-orphan drug development in Japan.
Kawakami A; Masamune K
Orphanet J Rare Dis; 2022 Nov; 17(1):408. PubMed ID: 36348359
[TBL] [Abstract][Full Text] [Related]
6. Randomized Controlled Trial Data for New Drug Application for Rare Diseases in Japan.
Kubota Y; Narukawa M
Ther Innov Regul Sci; 2022 Jul; 56(4):659-666. PubMed ID: 35478399
[TBL] [Abstract][Full Text] [Related]
7. [Current Status and Issues in Drug Development for Rare Cancers].
Kashitani Y; Takayama H; Hamada N; Go S; Tagami M; Sugihara T
Gan To Kagaku Ryoho; 2023 Nov; 50(11):1150-1154. PubMed ID: 38056864
[TBL] [Abstract][Full Text] [Related]
8. Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments.
Winstone J; Chadda S; Ralston S; Sajosi P
Orphanet J Rare Dis; 2015 Oct; 10():139. PubMed ID: 26511061
[TBL] [Abstract][Full Text] [Related]
9. Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe.
Schlander M; Adarkwah CC; Gandjour A
Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):171-9. PubMed ID: 25312018
[TBL] [Abstract][Full Text] [Related]
10. Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs.
Giannuzzi V; Landi A; Bosone E; Giannuzzi F; Nicotri S; Torrent-Farnell J; Bonifazi F; Felisi M; Bonifazi D; Ceci A
BMJ Open; 2017 Sep; 7(9):e017358. PubMed ID: 28893754
[TBL] [Abstract][Full Text] [Related]
11. [Orphan drugs : New opportunities for the treatment of rare diseases].
Beck M
Internist (Berl); 2016 Nov; 57(11):1132-1138. PubMed ID: 27527064
[TBL] [Abstract][Full Text] [Related]
12. Post-approval Studies for Rare Disease Treatments and Orphan Drugs.
Maier WC; Christensen RA; Anderson P
Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573
[TBL] [Abstract][Full Text] [Related]
13. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
14. Developing a patient-directed policy framework for managing orphan and ultra-orphan drugs throughout their lifecycle.
Menon D; Stafinski T; Dunn A; Wong-Rieger D
Patient; 2015 Feb; 8(1):103-17. PubMed ID: 25559762
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French medical pharmacology.
Micallef J; Boutouyrie P; Blin O
Fundam Clin Pharmacol; 2017 Dec; 31(6):685-694. PubMed ID: 28779530
[TBL] [Abstract][Full Text] [Related]
16. Pivotal studies of orphan drugs approved for neurological diseases.
Mitsumoto J; Dorsey ER; Beck CA; Kieburtz K; Griggs RC
Ann Neurol; 2009 Aug; 66(2):184-90. PubMed ID: 19743448
[TBL] [Abstract][Full Text] [Related]
17. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
18. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
Stockklausner C; Lampert A; Hoffmann GF; Ries M
Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
[TBL] [Abstract][Full Text] [Related]
19. Orphan drug development: an economically viable strategy for biopharma R&D.
Meekings KN; Williams CS; Arrowsmith JE
Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
[TBL] [Abstract][Full Text] [Related]
20. Cancer drugs for solid tumors approved by the EMA since 2014: an overview of pivotal clinical trials.
Lasala R; Logreco A; Romagnoli A; Santoleri F; Musicco F; Costantini A
Eur J Clin Pharmacol; 2020 Jun; 76(6):843-850. PubMed ID: 32125472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]